In this episode, Mike Garrett, CEO of Taconic Biosciences, discusses how preclinical research companies are helping drug developers navigate the current challenging funding environment. He explains that investors now demand more robust translational data showing real potential to impact human health, rather than just basic in vitro results, forcing researchers to generate better evidence packages earlier in development.This episode is presented in partnership with <a href="https://cresset-group.com/" target="_blank" rel="ugc noopener noreferrer">⁠⁠</a><a href="https://www.taconic.com/" target="_blank" rel="ugc noopener noreferrer">Taconic Biosciences</a>. Host<a href="https://www.linkedin.com/in/lorielliskatz/" target="_blank" rel="ugc noopener noreferrer">⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠</a>, Head of Insights, BioSpace Guest<a href="https://www.linkedin.com/in/garrettmike/" target="_blank" rel="ugc noopener noreferrer">Mike Garret</a>, CEO, Taconic Biosciences Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.